Candel Therapeutics Inc., trading under NASDAQ: CADL, has released a corporate presentation detailing significant developments in their cancer treatment programs. The company highlights their lead candidate, CAN-2409, as an off-the-shelf pan-solid tumor therapy designed to elicit an individualized anti-cancer immune response. The therapy has shown positive phase 3 results in localized, intermediate-to-high-risk prostate cancer, and positive overall survival data in phase 2a trials for both borderline resectable pancreatic cancer and therapy-resistant non-small cell lung cancer. Candel's pipeline also includes CAN-3110, an oncolytic HSV-1 designed for tumor-specific replication, with proof of concept published in _Nature_ for recurrent high-grade glioma. The company notes upcoming data releases for CAN-3110 in Q4 2025. Candel's financial position includes $92.2 million in cash and equivalents as of March 31, 2025, with an expected runway into Q1 2027. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.